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Abstract
Background: The Rho GTPases A, B and C proteins, members of the Rho family whose activity
is regulated by GDP/GTP cycling, function in many cellular pathways controlling proliferation and
have recently been implicated in tumorigenesis. Although overexpression of Rho GTPases has been
correlated with tumorigenesis, only their GTP-bound forms are able to activate the signalling
pathways implicated in tumorigenesis. Thus, the focus of much recent research has been to identify
biological tools capable of quantifying the level of cellular GTP-bound Rho, or determining the
subcellular location of activation. However useful, these tools used to study the mechanism of Rho
activation still have limitations. The aim of the present work was to employ phage display to identify
a conformationally-specific single chain fragment variable (scFv) that recognizes the active, GTP-
bound, form of Rho GTPases and is able to discriminate it from the inactive, GDP-bound, Rho in
endogenous settings.
Results: After five rounds of phage selection using a constitutively activated mutant of RhoB
(RhoBQ63L), three scFvs (A8, C1 and D11) were selected for subsequent analysis. Further
biochemical characterization was pursued for the single clone, C1, exhibiting an scFv structure. C1
was selective for the GTP-bound form of RhoA, RhoB, as well as RhoC, and failed to recognize
GTP-loaded Rac1 or Cdc42, two other members of the Rho family. To enhance its production,
soluble C1 was expressed in fusion with the N-terminal domain of phage protein pIII (scFv C1-
N1N2), it appeared specifically associated with GTP-loaded recombinant RhoA and RhoB via
immunoprecipitation, and endogenous activated Rho in HeLa cells as determined by
immunofluorescence.
Conclusion: We identified an antibody, C1-N1N2, specific for the GTP-bound form of RhoB from
a phage library, and confirmed its specificity towards GTP-bound RhoA and RhoC, as well as RhoB.
The success of C1-N1N2 in discriminating activated Rho in immunofluorescence studies implies
that this new tool, in collaboration with currently used RhoA and B antibodies, has the potential
to analyze Rho activation in cell function and tumor development.
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Background
The Rho GTPases proteins are members of a large super-
family of regulatory proteins whose activities are control-
led by regulated GDP/GTP cycling. To date, a total of 22
Rho family members have been suggested by the data
available from the human genome sequence project. The
Rho GTPases can be divided into six groups: Rho (RhoA,
RhoB, RhoC), Rac (Rac1, Rac2, Rac3, RhoG), Cdc42
(Cdc42, TC10, TCL, Chp/Wrch-2, Wrch-1), Rnd (Rnd1,
Rnd2, Rnd3/RhoE), RhoBTB (RhoBTB1 and RhoBTB2)
and Miro (Miro-1 and Miro-2). Additional members,
RhoD, Rif and TTF/RhoH, do not fall into any of these
subfamilies [1].
Rho GTPases control a wide variety of signal transduction
pathways regulating many fundamental processes of cell
biology, such as organization of the actin cytoskeleton [2],
gene expression, cell proliferation and survival [3]. Most
Rho proteins cycle between an active GTP-bound state
and an inactive GDP-bound state. Binding to GTP is pro-
moted by Rho guanine nucleotide exchange factors (Rho-
GEFs), and GTP hydrolysis is catalysed by Rho GTPase-
activating proteins (Rho-GAPs). Rho-GDP dissociation
inhibitors (Rho-GDIs) stabilize the GDP-bound form of
Rho proteins.
Rho proteins are also implicated in participating in several
steps of tumor progression and development of metastasis
[4,5]. Activated Rho proteins cooperate strongly with
oncogenes Ras and Raf in focus-formation assays, but
either fail to independently induce transformation or else
exhibit weak transforming activity [6-9]. They function in
cell cycle regulation by the modulation of cyclin D1 [10]
and by their involvement in endocytic traffic [11,12], such
as in regulation of epidermal growth factor receptor [13].
Furthermore, Lacal et al have shown that Rho GTPases are
directly involved in signalling pathways that trigger either
proliferation or cell death [14]. Moreover, expression of
activated Rac protects against Ras-induced apoptosis [15].
These studies linking Rho proteins to many aspects of cel-
lular proliferation are further extended by the study by
Gomez del Pulgar, which revealed that several human
tumors contained aberrant expression and activation of
Rho GTPases [16]. Elevated expression of RhoA and RhoC
was found in breast, lung, ovarian, gastric, and bladder
cancers. The involvement of RhoA in testicular human
tumors was demonstrated by increased RhoA mRNA lev-
els in relation to tumour grade [17]. Overexpression of the
rhoC gene in adenocarcinoma of pancreas correlated with
poorer prognosis of patients [18], whereas RhoB expres-
sion is lost in several tumors [19]. Moreover, unlike Ras,
no mutated, constitutively active forms of Rho proteins in
tumors have thus far been identified [20], apart from one
report linking hyperactive Rac3 with highly proliferative
human breast cancer cells and tumor tissues [21]. What-
ever the level of gene expressions of Rho GTPases and
assuming that high level of protein could be associate
with higher concentration of activated Rho GTPase, the
knowledge of accurate variations of the Rho activation
under treatment would be a significant progress in the
understanding of the biological role of Rho in oncogene-
sis.
To further develop understanding of Rho activation, we
identified a conformation-specific scFv against the active
form of RhoA, RhoB and RhoC GTPases. We employed a
phage display approach, which has previously demon-
strated successful results in generating precise sensors of
variations in molecular conformation [22]. To this end,
we utilized the Q63L mutant [23] of RhoB (locked in the
GTP binding structure), and expressed this mutant as a
GST fusion protein in E. coli and used the purified recom-
binant protein as a target ligand for selection of recom-
binant scFv. Using the Griffin.1 library [24], one clone
(C1) was selected for its ability to discriminate between
the activated versus the unactivated form of RhoB, as well
as RhoA and RhoC, but not other Rho family members.
The selected C1 scFv was fused to a fragment of phage coat
protein pIII gene to enhance its production, expressed in
E. coli, and its specificity confirmed. Finally, its ability to
detect endogenous activated Rho in vivo in immunofluo-
rescence studies is shown.
Results and Discussion
Identification of RhoBQ63L specific interacting phages
Peptide and protein libraries on filamentous phages, in
combination with effective selection strategies, have
proven to be a rapid and successful method to identify
proteins with specific binding properties. A major advan-
tage of the in vitro selection process by phage display is the
extensive control of the selection conditions, which, for
example, allowed the preservation of the three-dimen-
sional structure of GTP-bound form of Rho. Using the
Griffin.1 phage display library, Perez et al identified scFvs
that act as molecular conformation sensors by showing
selectivity towards the GTP-bound conformation of the
Rab6 GTPase [22]. The present work used the same
phagemid library containing more than 109 independent
clones. Each clone expresses human recombinant anti-
bodies as a single-chain Fv (scFv), where both myc, 6xHis
tags, and the pIII protein of M13 are fused to the C-termi-
nus of immunoglobulin VH-VL fusion (Fig 1).
Due to its ability to decrease the kinetics of GTP hydroly-
sis, RhoBQ63L is considered as a "GTP-locked" mutant of
RhoB. We expressed and purified the GST-tagged
RhoBQ63L mutant in Escherichia coli, and used the
recombinant protein as target for phage selection. For the
first round of selection, we collected phage bound to GST-BMC Biotechnology 2008, 8:34 http://www.biomedcentral.com/1472-6750/8/34
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pHEN2 vector and construction of scFv C1-N1N2 Figure 1
pHEN2 vector and construction of scFv C1-N1N2. A: Schematic representation of the pHEN2 phagemid vector (Griffin 
1. library). pelB leader: signal peptide sequence of bacterial pectate lyase that mediates secretion into the periplasmic space; VH 
: variable fragment of the heavy chain; VL: light chain; 6xHis: 6 histidine-tag; myc: myc-tag; amber: amber stop codon; N1, N2, C-
term: portions of the N- and C-term of phage capside protein pIII; LMB3 and pHENSeq: primers used for sequencing the VH and 
VL domain. B: Schematic construction of vectors encoding soluble scFv C1 and scFv C1-N1N2. The amber stop codon 
between the scFv and gene III in pHEN 2 was removed by mutagenesis (middle construct). The C-terminal portion of pIII was 
removed in the final pHEN C1-N1N2 vector (bottom construct), first by PCR amplification of pHEN C1-pIII, introducing an 
EcoRI site after N2, and subsequently by cloning the NcoI and EcoRI digested PCR product into the linearized pHEN C1-pIII 
plasmid at the NotI and EcoRI sites. H: 6 histidine-tag; M: myc-tag.
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RhoBQ63L-bound beads. For the subsequent four
rounds, selection was a two-part process: we first preb-
locked phage on GST-beads, and the phage mixture was
then loaded on GST-RhoBQ63L beads. During the last
round, soluble recombinant wild-type RhoB was added
into the phage mixture to specifically select phage that
interact only with the active GST-RhoBQ63L form on the
beads. Rounds IV and V contained polyclonal phage spe-
cific to GST-RhoBQ63L. To increase isolation of positive
clones, we initiated two independent screenings from
round V: V-1 and V-2. In total, 144 (48 from the V-1 and
96 from the V-2) clones were randomly picked and
checked by ELISA, yielding 8 RhoBQ63L selective phages.
Characterization of the selected single chain antibodies
To characterize the 8 RhoBQ63L selective phages, their
specificity was first examined by analyzing their interac-
tion with GST, GST-RhoB and GST-RhoBQ63L (Fig 2A).
Six of the phages showed preferential binding to the GTP-
locked RhoBQ63L mutant, while two clones (E2 and E12)
failed to interact and were discarded (Fig 2A).
To assess the specificity of the selected scFv against the
GTP-bound form of the three Rho proteins of interest, C1
and control phages were tested by ELISA with the wild
type form of RhoA, B and C (WT) and their corresponding
active forms (Q63L). As shown in Fig 2B, C1 phage
showed significant reactivity against the Q63L mutant of
all three Rho proteins. In contrast, the reactivity against
the WT form was very low in most cases, and within the
range of the background response. As predicted, the C1
phage does not discriminate between the GTP-bound
form of RhoA, B, C, suggesting that C1 is directed against
the GTP binding domain or against the effector-binding
domain shared at almost 100% identity among the three
proteins. This also suggests that the carboxy terminal
hyper-variable domain of these proteins, which functions
to target membrane localization, has little importance in
the conformation of the active form.
DNA sequencing of the 6 preselected clones revealed three
unique scFv sequences for phages C1, D11 and A8 (Fig 3),
although scFv D11 and A8 only contained sequence for
the variable heavy chain, VH. The major differences
between the amino-acid sequences of the three clones
were concentrated in the hypervariable complementary-
determining regions, CDR2 and CDR3, of the VH. The A8
and D11 phages proved to be unstable. They quickly lost
their recognition properties, and were discarded. Thus,
only the C1 phage was kept for further analysis.
Biochemical characterization of the specific binding of 
scFv C1
In order to further determine whether C1 specifically
detected Rho proteins in their GTP-bound conformation,
we next assayed C1 binding to Rho protein preloaded
with GTP. First, GST-RhoA expressed and purified onto
glutathione beads was loaded with GDP or the slowly
hydrolyzable analogue of GTP, GTPγS, to ensure maxi-
mum loading of RhoA with the nucleotide [25]. C1 phage
was next added and incubated for 1 hour, and bound C1
phages were measured with anti-M13. As seen in Fig 4A,
the C1 binding increased up to 75 min after loading with
GTPγS until a steady state was reached. Under similar
incubation conditions, in the presence of GDP, the C1
phage recognition of RhoA did not change. To further
confirm the Rho GTP-bound conformational specificity of
C1, nucleotide-binding assays with RhoB and RhoC were
tested in comparison with RhoA. C1 phages bound specif-
ically to GTPγS but not GDP preloaded RhoA, RhoB and
RhoC (Fig 4B).
Interestingly, when we tested the binding of C1 phage
against the GTP-bound form of Rac1 and Cdc42, two well-
characterized members of two separate subfamilies of Rho
GTPases, C1 phages bound selectively on GTPγS-RhoB
but not GTPγS-Rac1 or GTPγS-Cdc42 (Fig 4C), despite
their ability to successfully bind GTP (insert Fig 4C).
Together this demonstrated that the scFv C1-pIII fusion
protein specifically targeted the GTP-bound form of
RhoA, RhoB and RhoC, and was unable to recognize
GTPγS or GDP preloaded Rac1 and Cdc42, two other Rho
subfamily members.
Expression and activity analysis of recombinant scFvC1
To further characterize scFv C1 binding, we constructed
and expressed recombinant scFv C1 protein. The pHEN2
phagemid vector carries an amber codon (TAG) at the C-
terminal of the scFv sequence and prior to the M13 pIII
sequence (Fig 1B, top panel). Non-suppressive strains,
such as BL21, interpret the amber codon as a translation
stop signal, thus the scFv C1 is expressed in soluble form
and can be purified via the histidine tags. Crude bacterial
extract from cells expressing scFv C1, as confirmed by
Western Blot analysis with anti-c-myc antibodies, lost its
ability to bind RhoAQ63L (Fig 5A). The multiple supple-
mentary bands observed in the blot would be explained
by the renowned propensity of scFv to form dimeric and
higher-order aggregates. This loss of function is a com-
mon observation when phage-display derived scFvs are
expressed as soluble scFvs. Jensen et al. reported that an
inactive antibody fragment can be functionally rescued by
fusion to the N-terminal domain of the original phage dis-
play fusion partner, filamentous phage protein III [26].
We employed a similar approach and mutated the amber
codon to allow translation and fusion to the N terminal of
pIII, as well as removed the C terminal of pIII (Fig 1B, scFv
C1-N1N2, bottom panel). As shown in Fig 5B, scFv C1-
N1N2 exhibited the predicted molecular mass of 60 kDa.
Furthermore, the bacterial lysate expressing scFv C1-BMC Biotechnology 2008, 8:34 http://www.biomedcentral.com/1472-6750/8/34
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Phage binding specificity towards RhoQ63L compared to wild-type Rho Figure 2
Phage binding specificity towards RhoQ63L compared to wild-type Rho. A: Ten monoclonal phages from E. coli 
supernatant were analyzed for binding to GST (grey columns), GST-RhoB (white columns) and GST-RhoBQ63L (black col-
umns) protein immobilized on an ELISA plate. Bound phages were detected with horseradish peroxydase-labeled anti-M13 
using TMB as substrate. Helper phage was used as a control. Results are expressed as absorbance at 480 nm. Insert: ratio of 
absorbance of binding to RhoBQ63L to absorbance of binding to RhoB. B: Selectivity of C1 phages on WT and activated Q63L 
form of Rho. 1010 clones of C1 (black columns) and control (white columns) phage were analyzed for binding to GST-RhoA, 
RhoB and RhoC, both wild type (WT) and Q63L forms, immobilized on a glutathione ELISA plate. Bound phages were 
detected with horseradish peroxydase-labeled anti-M13 using TMB as substrate. Results are expressed as absorbance at 480 
nm. Concentrations of GST-Rho proteins in each well were monitored by anti-GST (not shown). The graph is representative 
for 3 experiments, and each binding assay was performed in duplicate.BMC Biotechnology 2008, 8:34 http://www.biomedcentral.com/1472-6750/8/34
Page 6 of 14
(page number not for citation purposes)
N1N2 was now able to selectively recognize RhoAQ63L
versus RhoA as determined by ELISA. Competitive experi-
ments between scFvC1-N1N2 and the Rho binding
domain of Rhotekin (RBD) have been analyzed and are
summarized in Table 1. RBD alone is not stable enough to
be used in this study, however the chimere GST-RBD is
able to compete with scFvC1-N1N2 on RhoAQ63L and
shows an affinity more than 10 fold higher than the scFv
C1-N1N2. Affinities for GDP-Rho, GTP-Cdc42 and GTP-
Rac1 are too weak to be determined.
The new recombinant C1-N1N2 fusion protein was
expressed more easily in a soluble form, and showed
higher binding to RhoAQ63L. We then purified scFv C1-
N1N2 from crude extract by incubation with Ni-NTA aga-
rose beads and elution with imidazole, and aliquots from
each step were analyzed by SDS PAGE (Fig 6A). The bind-
ing activity towards RhoAQ63L of scFv C1-N1N2 crude
extract and the four elutions fractions were tested and con-
firmed by ELISA (Fig 6B). As seen on the SDS PAGE vari-
ous proteins with lower molecular mass than scFvC1-
N1N2 are co-purified with the desired probe. As reported
by others these proteins would be the result of transla-
tional arrest in the N1N2 sequence of the phage PIII.
To measure the affinity of this scFv, surface plasmon reso-
nance (SPR) experiments were performed on a Biacore
3000 instrument [27]. Using the previously described
methodology by Horn et al, we bound GST-RhoA loaded
with GDP on one flowcell (FC1), and GST-RhoA loaded
with GTPγS on a second flowcell (FC2) [28]. C1-N1N2
"antibody" was injected at a concentration of 2.5 and 8
µM using a flow rate of 20 µl/min. In order to test the spe-
cificity of scFv C1-N1N2 for the GTP-bound form of
RhoA, differential responses (FC2-FC1) were recorded
and analyzed using the Biaevaluation 4.0 software
(Biacore AB). The results supported the GTP-bound con-
formational specificity, with an apparent dissociation
constant (KD) in the range of 3 ± 1 µM (data not shown).
Similarly, affinity of a scFv molecule for GTP-bound Ras
was previously reported in the range of 1.3 µM [29]. Same
results were found with GST-Cdc 42 and GST-Rac 1
loaded with GTPγS are coated on FC1 in front of GST-
RhoA loaded with GTPγS on FC2.
Recombinant scFv C1-N1N2 used as sensor of GTP-bound 
Rho in vitro and in vivo
We determined the ability of the antibody to immunopre-
cipitate RhoA and RhoB in their GTP-bound conforma-
tions. Crude bacterial extracts expressing scFv C1-N1N2
was incubated with Ni-NTA beads to immobilize the anti-
body, and bacterial lysate containing recombinant RhoA
or RhoB preloaded with GDP or GTP were mixed with
these beads. RhoA and RhoB specifically bound to the
scFv C1-N1N2 beads were analysed by Western Blot with
commercial anti-RhoA and anti-RhoB antibodies (Fig
Amino-acid sequence analysis of the identified scFvs specific for RhoBQ63L binding Figure 3
Amino-acid sequence analysis of the identified scFvs specific for RhoBQ63L binding. Amino-acid sequence align-
ments of the VH and VL regions of the scFvs C1, D11 and A8 compared to the human immunoglobulins sequences (imgt). 
Sequences highlighted in red vary from the amino-acid sequence of scFv C1. Underlined sequences correspond to CDR. Aster-
isks indicate the missing amino-acid that would generate the usual CDR.
VH
CDR-1 CDR-2
1 E V Q L V E S G G G L V Q P G G S L R L S C A A S G F T F S S Y A *  *  * * M S W V R Q A P G K G L E W V S A I S G S G G S T *  *  * C1
1 E V Q L V E S G G G L V Q P G G S L R L S C A G S G F T F S S Y A *  *  * * M H W V R Q A P G K G L E W V S A I G T G G G T* *  *  * D11
1 E V Q L V E S G G G L V Q P G G S L R L S C A A G G F T F S S Y A *  *  * * M H W V R Q A P G K G L E W V S A I G T G G G T *  *  *  * A 8
CDR-3
63 Y Y A D S V K G R F T I S R D N S K N T L Y L Q M N S L R A E D T A V Y Y C A R S D A A G N P S R *  *  * W G Q G T L V T V C1
62 Y Y A D S V K G R F T I S R D N A K N S L Y L Q M N S L R A E D T A V Y Y C AR   N R G A P G I D K V T *  W G Q G T L V T V   D11
62 Y Y A D S V K G R F T I S R D N A K N S L Y L Q M N S L R A E D T A V Y Y C ARL W G R A S S T Q E P N W G Q G T L V T V  A8
VL
CDR-1 CDR-2
1  S S E L T Q D P A V S V A L G Q T V R I T C Q G D S L R S Y Y *  *  * * * * A S W Y Q Q K P G Q A P V L V I Y G K N N *   *   ***** C1
CDR-3
54 R P S G I P D R F S G S S S G N T A S L T I T G A Q A E D E A D Y Y C N S R D S S G N H A Y V F G G G T K L T V L G  C1BMC Biotechnology 2008, 8:34 http://www.biomedcentral.com/1472-6750/8/34
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Specificity of C1 phage binding to GTP-bound Rho family members Figure 4
Specificity of C1 phage binding to GTP-bound Rho family members. A: Kinetics of GTP loading on RhoA. GST-RhoA 
immobilized on gluthatione beads was loaded with 100 µM of GDP and GTPγS at 37°C. 1011clones of C1 phages were incu-
bated with loaded (GTP or GDP) GST-RhoA-bound beads. Bound phages were detected with horseradish peroxydase-labeled 
anti-M13 using TMB as substrate. Results are expressed as absorbance at 480 nm. The graph is representative of 2 independ-
ents experiments. GST-RhoA, B and C (B) and GST-RhoB, Rac1 and Cdc42 (C) were loaded with 200 µM of GDP or GTPγS 
for 30 min and purified on glutathione ELISA plates. 1010 clones of C1 phages were incubated in each well. Bound phages were 
detected with horseradish peroxydase-labeled anti-M13 using TMB as substrate. Results are expressed as absorbance at 480 
nm. Amount of GST protein was quantified with goat anti-GST antibody followed by horseradish peroxydase-labeled anti-goat 
(not shown). The graph is representative of 3 experiments, each binding assay performed in duplicate. Insert: Specific radioac-
tivity binding of [35S] GTPγS on RhoB, Rac1 and Cdc42. GST-RhoB, Rac1 and Cdc42 were loaded with 20 nM [35S] GTPγS in 
the presence (non specific binding) or not (total binding) of 200 µM unlabeled GTP for 30 minutes at 37°C and purified on glut-
hatione ELISA plates. Radioactivity was measured in each well. The difference between the total binding and the non specific 
binding represent the specific binding. The graph is representative of 2 experiments, each performed in triplicate.
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Binding activity of scFv C1 compared to scFv C1-N1N2 Figure 5
Binding activity of scFv C1 compared to scFv C1-N1N2. (A) scFv C1 and (B) scFv C1-N1N2 crude extracts analyzed 
by (1) Western Blot and (2) ELISA. (1) scFvs were resolved on 12,5% SDS-PAGE, immunoblotted with c-myc antibody, and vis-
ualized by enhanced chemiluminescence as described in Methods. (2) scFvs from crude extract were analysed for binding to 
GST-RhoA and GST-RhoAQ63L protein immobilized on an ELISA plate. Bound scFvs were detected with horseradish peroxy-
dase-labeled anti-c-myc using TMB as substrate. Results are expressed as absorbance at 480 nm. Graphs are representative of 
6 experiments, each performed in duplicate.BMC Biotechnology 2008, 8:34 http://www.biomedcentral.com/1472-6750/8/34
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7A). The scFv C1-N1N2 on Ni-NTA beads selectively asso-
ciated with the GTP-bound form of both RhoA and RhoB,
confirming the specificity of this new antibody.
The ability of scFv C1-N1N2 to identify activated Rho was
next tested in vivo on activated HeLa cells by immunoflu-
orescence. After serum deprivation (48 h), HeLa cells were
activated 1 hour with EGF (100 ng/ml) and serum (FBS
10%) and immunostained with scFvC1-N1N2, irrelevant
scFv (anti-thyroglobulin) and anti-c-myc antibodies. We
observed that staining with scFv C1-N1N2 (Fig. 7B panel
A andB), but not the irrelevant scFv (Fig. 7B panelF), pro-
duced a positive immunofluoresence signal specifically in
activated cells (Panel B). To confirm the signal specificity,
prior to staining, scFv C1-N1N2 was first incubated with
GTPγS- preloaded RhoA to exhauste the selective scFv
(negative control) or GDP-preloaded RhoA which would
have any effect on scFv activity (positive control). On
serum starved cells, little signal was detected with either
the scFv C1-N1N2 antibody preincubated with GDP-
bound RhoA (Fig 7B panel A) or GTPγS-bound RhoA (not
shown), although Rho A is detected by a commercial anti-
body (Fig 7B panelD). Upon activation, a signal was visu-
alized with the scFv C1-N1N2 preincubated with GDP-
bound RhoA (Fig 7B panel B), showing labelling of the
plasma membrane and punctate cytoplasmic structures
consistent with previous reports for Rho localization [30].
Similar labelling is obtained with commercial anti-RhoA
(Fig 7B panel E). Moreover, this signal was suppressed by
preincubation of the scFv C1-N1N2 antibody with GTPγS-
preloaded RhoA (Fig 7B panel C). This data strongly sug-
gests that scFv C1-N1N2 is able to recognize endogenous
activated and GTP-bound Rho at the cellular level.
Conclusion
Binding domains of effector proteins have proven to be
useful as conformational sensors in analyzing the spatio-
temporal activation of GTPases [31,32]. In this study, we
have shown that a phage display approach identified a
specific phage for the GTP-bound form of RhoA, B and C.
The expressed and purified scFvC1-N1N2 protein pro-
ceeded from this phage is able to recognize the three Rho
proteins (A, B and C) loaded with GTPγS with great specif-
icity, and detect activation of endogenous Rho protein in
fixed cells. This finding implicates the potential for scFv
C1-N1N2 as a useful tool to compare the level of activated
Rho in cancer tissues versus normal tissues.
Methods
Construction of pHEN vectors
The schematic for vector construction is presented in Fig-
ure 1. Quick-Change (Stratagene) was used to remove the
amber stop codon between scFv and protein III genes in
pHEN 2, using the following primers: 5'CTGAAT-
GGGGCCGCAGAGACTG TTGAAAGTTG 3' and
5'CAACTTTCAACAGTCTCTGCGGCCCCATTCAG 3'. A
new EcoRI site was introduced downstream of the pIII N2
region by PCR amplification of this modified plasmid
(pHEN C1-pIII) using primers LMB3, 5'-CAG-
GAAACAGCTATGAC-3', and N2 (EcoR1), 5'CCGGA
ATTCGCCGCCGCCAGCATTGAC 3'. The final pHEN C1-
N1N2 vector was constructed by cloning the NcoI/EcoRI
digested PCR product into the NcoI and EcoRI digested
pHEN C1-pIII plasmid. Constructs were verified by
sequencing.
GST-fusion vectors and protein expression
The Q63L mutation of RhoA, RhoB, and RhoC was gener-
ated in the original wild-type cDNA of RhoA, RhoB, RhoC
(a gift from Dr. P. Sheffield [33]) cloned into the
pGSTparallel2 vector, in frame at the 3' of glutathione-S-
transferase, using the QuickChange Site-Directed Muta-
genesis kit (Stratagene). The primer for RhoAQ63L 5'
GGACACAGCTGGGCTCGAGGATTATGATCG 3', for
RhoBQ63L, 5' GGACACGGCGGGCCTCGAGGACTAC-
GACCG 3' and for RhoCQ63L 5' GGACACAGCAG-
GGCTCGAGGACTATGATCG 3', introduce an internal
XhoI restriction site in the pGSTparallel2 DNA sequence.
pGEX plasmids expressing GST-Cdc42 and GST-Rac1 were
kindly provided by Dr. A. Blangy (CRBM-CNRS, France).
Recombinant GST fusion Rho proteins were expressed
and purified in a protease deficient strain (E. coli BL21).
Bacteria were grown at 37°C in 1 liter of LB medium con-
taining 100 µg/ml ampicillin until an OD600 = 0.4 was
reached. Protein expression of RhoA, RhoB, RhoC and Rac
was induced by overnight incubation (3 hours for Cdc42)
with 0.1 mM of isopropyl-β-D-glactopyranoside (IPTG) at
20°C, and cells were harvested. Bacteria pellets were fro-
zen at -20°C for 15–20 minutes, and subsequently resus-
pended at 4°C in 50 mM Tris-HCl, pH 7.5, 150 mM NaCl,
Table 1: ELISA competition studies on RhoAQ63L coated plate. ScFvC1-N1N2 (0.4 µM) is competed by increasing concentrations of 
GST-RBD, GDP bound RhoA, GTP bound Cdc 42, GTP bound Rac 1. KD of GST-RBD was also determined by surface plasmon 
resonance on GST-RhoAQ63L.
GTP-RhoA GDP-RhoA GTP-Cdc42 GTP-Rac1
GST-RBD KD (µM) 0.2 ± 0.2 > 50 > 50 > 50
ScFvC1N1N2 KD (µM) 3 ± 1 > 50 > 50 > 50BMC Biotechnology 2008, 8:34 http://www.biomedcentral.com/1472-6750/8/34
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Characterization of enriched scFv C1-N1N2 Figure 6
Characterization of enriched scFv C1-N1N2. A: scFv from crude extract was purified on Ni-NTA beads. Fractions (20 
µl) were resolved on a 12.5% SDS-PAGE gel, and visualized by Coomassie Blue staining. Crude: total extract; flush: non bound 
scFv; El (1–4): elution fractions 1 to 4. B: Each step of purification (1:10 diluted elutions in 3% milk-PBS) was analyzed for bind-
ing to GST-RhoA and GST-RhoAQ63L protein immobilized on an ELISA plate. Bound scFv were detected with horseradish 
peroxydase-labeled anti-myc using TMB as substrate. Results are expressed as absorbance at 480 nm. Graphs are representa-
tive of more than 5 experiments, each performed in duplicate.
A
B
scFv C1-N1N2
37
75
50
crude   Flush   El1   El2    El3    El4BMC Biotechnology 2008, 8:34 http://www.biomedcentral.com/1472-6750/8/34
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scFv C1-N1N2 specifically recognizes GTP-bound Rho in vitro and in vivo Figure 7
scFv C1-N1N2 specifically recognizes GTP-bound Rho in vitro and in vivo. A: scFv C1-N1N2 immunoprecipitation 
(IP) of GTP-bound RhoA and RhoB. Crude bacterial lysates of recombinant RhoA and RhoB loaded with either GTP or GDP 
were incubated with scFv C1-N1N2 fixed on Ni-beads. An irrevelant scFv was used as control. Complexes on beads were 
resolved by SDS-PAGE and immunobloted with anti-RhoA and anti-RhoB. Western Blot is representative of 2 independent 
experiments. B: Immunofluorescence shows that scFv C1-N1N2 specifically binds to activated HeLa cells. Suspension contain-
ing scFv C1-N1N2 was incubated with GDP-loaded RhoA(A and B) or GTPγS-preloaded RhoA beads (C). Twenty-four hours 
after seeding, HeLa cells were serum-starved for 48 h and activated with 10% SVF and EGF (100 ng/ml) for 1 hour. Cells were 
fixed, permabilized and incubated with supernatants from scFv C1-N1N2-Rho incubation and anti-c-myc FITC conjugate sec-
ondary antibody. (A) Non-activated HeLa cells incubated with the antibody scFv C1-N1N2 preincubated with GDP-loaded 
RhoA beads, (B) EGF-activated HeLa cells incubated with the antibody scFv C1-N1N2 preincubated with GDP-loaded RhoA 
beads (C) EGF-activated HeLa cells incubated with the antibody scFv C1-N1N2 preincubated with GTPγS-loaded RhoA beads. 
(D) Non-activated HeLa cells incubated with the commercial Rhoa antibody, (E) EGF-activated HeLa cells incubated with the 
commercial RhoA antibody, (F) EGF-activated HeLa cells incubated with irrelevant scFv (anti-tyroglobulin). Pictures are repre-
sentative of 2 independent experiments.BMC Biotechnology 2008, 8:34 http://www.biomedcentral.com/1472-6750/8/34
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5 mM MgCl2 (PBS, 2 mM MgCl2 for Cdc42) at 1:100 or
1:10 of the original culture volume. Cells were incubated
on ice for 30 minutes, sonicated for three 10 sec rounds,
and lysate was centrifuged at 7,000 × g for 30 minutes. The
supernatant was purified by Reacti-Bind™ glutathione
coated strip-well plates (Pierce) or by glutathione sepha-
rose beads (Amersham Pharmacia Biotech) according to
the manufacturer's instructions.
Phage libraries and antibody phage display screening
The Griffin.1 library [24], a human synthetic VH+VL scFv
phage library in a phagemid vector, and the positive con-
trol Escherichia coli TG1 (TG1 containing an anti-tyroglob-
ulin clone) were generously provided by Fiona Sait of The
Medical Research Council (Cambridge, England). We fol-
lowed the protocol provided with the Griffin.1 library
[34], as previously described [35]
Briefly, for the first round of selection, phages were incu-
bated with GST-RhoBQ63L-bound glutathione beads (10
µg of Rho protein). For the subsequent three rounds,
bound unspecific phages were removed by first incuba-
tion with GST-beads, and unbound phages were incu-
bated with GST-RhoBQ63L beads, then eluted and
amplified. For the last round, the phages bound on GST-
RhoBQ63L beads were competed with soluble wild type
recombinant RhoB (80 µg).
Reactivity of the identified phages was tested with ELISA
and positive clones were sequenced. Phagemids DNAs
from individuals colonies were extracted and purified
with the Quiafilter plasmid purification kit (Qiagen) and
sequenced with the primers LMB3 5'-CAG-
GAAACAGCTATGAC-3' and pHENseq 5'-CTATGCG-
GCCCCATTCA-3'. The sequences are compared to the
human immunoglobulins sequences and aligned with FR-
IMGT and CDR-IMGT delimitation [36].
Monoclonal phage ELISA
Briefly, recombinant GST-Rho proteins were incubated on
Reacti-Bind™ glutathione coated plates for 1 hour at room
temperature. One group of 48 colonies and another of 96
colonies from the fifth round of selection were picked
manually and tested by ELISA as previously described
[37].
Kinetics of Rho GTP loading
Recombinant GST-RhoA purified on glutathione beads
was loaded with 0.1 mM of GDP or GTPγS in PBS 10 mM
EDTA at 37°C. Loading was repeated several times. A sus-
pension of C1 phages (1011 clones) in 3% MPBS, 10 mM
MgCl2 was incubated with loaded GST-RhoA beads for 1
hour at room temperature. Beads were washed 3 times
with 0.1% Triton ×100 in PBS. A suspension of peroxi-
dase-labeled anti-M13 antibody (1:5000 dilution in 2%
milk in PBS) was added for 1 hour and the reaction was
assayed, using 3,3',5,5' tetramethylbenzidine substrate
(Sigma). The reaction was stopped by adding 1 M sulfuric
acid, and the absorbance was read at 480 nm.
Production and purification of soluble single-chain Fv 
antibody
BL21 E coli non-suppressor strain was transformed with
the selected pHEN plasmid, and a selected colony was
grown in 100 mL of 2xTY medium containing 100 µg/mL
ampicillin and 2% glucose at 37°C. At proper concentra-
tion (OD600 = 0.8), the culture was centrifuged at 3,300 ×
g for 10 minutes at 4°C. Bacteria were resuspended in
2xTY medium containing 100 µg/mL ampicillin and
induced with 0.1 mM IPTG overnight at 30°C (no more
than 16 h). Bacteria were harvested, resuspended in sphe-
roplast buffer (200 mM Tris-HCl, pH 8, 0.5 mM EDTA,
0.5 M sucrose) at 1:10 of the culture volume and incu-
bated on ice for 30 minutes. The sample was centrifuged
at 3,300 × g for 10 minutes, and the supernatant contain-
ing the scFv was directly subjected to ELISA analysis.
For scFvs purification, bacteria were harvested, resus-
pended in 50 mM Tris-HCl, pH 7.5, 150 mM NaCl, 2.5
mM MgCl (1/10 of the culture volume), incubated on ice
for 30 minutes and sonicated five rounds for 10 sec. The
cell lysate was centrifuged at 3,300 × g for 10 minutes, and
the supernatant was centrifuged at 17,500 × g for 1 hour.
The supernatant containing the scFvs was adjusted to 300
mM NaCl and 1 mM imidazole, and the scFvs were con-
centrated on 1 ml of 50% slurry Ni-NTA agarose (Qiagen)
at 4°C with shaking for at least two hours. After washing
with 50 mM Tris-HCl, pH 7.5, 300 mM NaCl, 10 mM imi-
dazole, bound scFvs were eluted with 50 mM Tris-HCl,
pH 7.5, 300 mM NaCl, 250 mM imidazole. Samples of all
fractions were analysed by SDS-PAGE. ScFvs-containing
fractions were pooled and applied to a PD-10 column
(G25M Sephadex, GE Healthcare) equilibrated with 50
mM Tris-HCl, pH 7.5. Desalted scFvs were analyzed by
SDS-PAGE and Coomassie blue staining or Western blot-
ting with anti-c-myc. All fractions containing scFvs were
tested by ELISA in conditions detailed above.
Antibodies
Mouse anti-RhoA (26-C4) and rabbit anti-RhoB (sc-180)
antibodies were obtained from Santa Cruz Technology
(Santa Cruz, CA); goat anti-GST, mouse anti-M13 (HRP)
antibodies were obtained from Amersham Pharmacia
Biotech (AB, Les Ulis, France); goat anti-c-myc (HRP) anti-
bodies were obtained from Interchim (Montluçon,
France), mouse anti-c-myc-FITC conjugate antibodies
were obtained from Zymed (Invitrogen, Cergy Pontoise,
France).BMC Biotechnology 2008, 8:34 http://www.biomedcentral.com/1472-6750/8/34
Page 13 of 14
(page number not for citation purposes)
Immunoprecipitation-Western Blot analysis
Crude protein lysates containing recombinant RhoA and
RhoB were loaded with 2 mM GDP or 0.2 mM GTPγS in
PBS, 10 mM EDTA for 30 min at 30°C. For immunopre-
cipitation, beads bound by scFv C1-N1N2 or scFv control
(anti-tyroglobulin) antibodies were incubated with
loaded Rho protein suspension for 45 min at 4°C. Beads
were washed 3 times with 50 mM Tris-HCl, pH 7.5, 150
mM NaCl, 30 mM MgCl2, 0.1% Triton ×100. To remove
scFv-protein complexes, beads were denatured in 2X Lae-
mmli reducing sample buffer, boiled for 5 minutes and
separated on 12.5% SDS-PAGE for Western Blot analysis
with anti-RhoA or anti-RhoB antibodies followed by HRP-
conjugated secondary antibodies. Protein detection was
performed using the enhanced and chemiluminescence
(ECL) system.
Guanine nucleotide-binding assay
Recombinant GST-RhoB, GST-Rac1 and GST-Cdc42 were
preloaded with [35S] GTPγS (1000 Ci/mmol, 1 mCi/mL,
GE Healthcare) or with [3H] GDP (12 Ci/mmol, 1 mCi/
mL, GE Healthcare) at different concentrations (0.2 to 20
10-9 M) in 10 mM EDTA for 30 min at 37°C. Specific
binding was obtained in the presence of 0.2 mM unla-
beled nucleotide. Loaded crude extracts were purified on
Reacti-Bind™ glutathione coated plates for 1 hour at room
temperature. Plates were washed twice with PBS 0.05%
Tween-20. 1 N NaOH was added to wells to remove
bound GST-Rho, and supernatant was collected and
diluted in the cocktail used for counting aqueous samples
(Ultima Gold, PerkinElmer). Radioactivity bound to GST-
Rho was determined by scintillation counting.
Immunofluorescence
Recombinant GST-RhoA fixed on beads (about 600 µg of
protein) was loaded with 100 µM GTPγS or GDP in 10
mM EDTA for 1 hour at 37°C. Purified scFvs (0.5 mg/ml)
was incubated with beads for 1 hour at room temperature,
and incubation was repeated twice. HeLa cells (ATCC,
CCL-2) grown on coverslips were stimulated with 100 ng/
ml of EGF (Sigma) and 10% FBS for one hour, then fixed
with paraformaldehyde (Cytofix) and permeabilized with
Cytoperm (BD Biosciences). Supernatant alone or con-
taining scFvs after incubation with loaded beads was incu-
bated with cells for 90 minutes. Coverslips were rinsed
once in PBS, 5 mM MgCl2 and incubated with 2 µg/ml of
anti-c-myc FITC conjugate secondary antibody (9E10,
Zymed). Staining was visualized using a Nikon eclipse 90i
microscope equipped with fluorescence FITC filters (Sem-
rock) and a CoolsnapHQ2 camera (Ropper). Images were
acquired using NIS-Element Ar.
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